Complement component C9 Antibodies

Complement component C9 (C9)

Constituent of the membrane attack complex (MAC) which plays an integral role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells (PubMed:9634479, PubMed:9212048, PubMed:26841934). C9 is the pore- forming subunit of the MAC (PubMed:4055801, PubMed:26841934).

.

Gene Information

Human
Gene Name:	C9
Uniprot:	P02748
Entrez:	735

Family

Belongs to:
complement C6/C7/C8/C9 family

Alternative Names

complement component 9; Complement Component C9

Molecular Weight

Mass (kDA):
63.173 kDA

Genomic Context

Human
Location:	5p13.1
Sequence:	5; NC_000005.10 (39284140..39364495, complement)

Tissue Specificity

Plasma (at protein level).

Subcellular Localizations

Secreted. Target cell membrane; Multi-pass membrane protein. Secreted as soluble monomer. Oligomerizes at target membranes, forming a pre-pore. A conformation change then leads to the formation of a 100 Angstrom diameter pore.

Diseases

• Hemolysis (disorder)
• Inflammation
• Neoplasms
• Malignant Neoplasms
• Glomerulonephritis
• Infective Disorder
• Lupus Erythematosus, Systemic
• Kidney Diseases
• Arthritis
• Proteinuria Of Undiagnosed Cause
• Edema
• Rheumatoid Arthritis
• Melanoma

• Autoimmune Diseases
• Nephritis
• Carcinoma
• Hemoglobinuria
• Paroxysmal Nocturnal Hemoglobinuria
• Autoimmune Reaction
• Malignant Paraganglionic Neoplasm

Pathways

• Complement Activation
• Pathogenesis
• Localization
• Cell Death
• Secretion
• Cytolysis
• Transport
• Proteolysis
• Immune Response
• Glycosylation
• Coagulation
• Virulence
• Inflammatory Response

• Cell Proliferation
• Excretion
• Cell Cycle
• Phagocytosis
• Opsonization
• Platelet Aggregation
• Cell Activation

PTMs

• Cleavage
• Oxidation
• Phosphorylation
• Glycosylation
• Reduction
• Acetylation
• Hydroxylation
• Methylation
• Carboxylation
• Acylation

• Deacetylation
• Gpi Anchoring
• Sulphation
• Dephosphorylation
• Deglycosylation
• Demethylation
• Ubiquitination
• Palmitoylation
• C-mannosylation
• Ribosylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/C9

Boster Bio Anti-C9 (H216) Primary Antibody - Best Uses Of The C9 Marker

The Anti-C9 (H216) Primary Antibody from Boster Bio can be a powerful tool for research, but how do you maximize its use? In this article, we will discuss how to optimize it, identify its benefits, and troubleshoot it to get the most from it. Let's dive in! Read on to find out more! Until then, have fun optimizing your experiments!

Boster Bio's Anti-C9 (H216) Primary Antibody

The Boster Bio Anti-C9 (H216) Primary antibody reacts with human, mouse, and rat cells. It is a Y-shaped protein produced by the immune system to recognize specific proteins and molecules. These antibodies have many applications in research, including immunohistochemistry, Western blotting, and cytokine analysis. The company also offers several other cytokine antibodies. Their antibody collection includes antibodies for cancer, stem cells, neuroscience, veterinary, innate immunity, and more.

Optimization

When optimizing experiments, it is important to know which controls to include in your sample. There are several choices you should make and using the right controls can help you achieve the desired result. Follow the steps outlined in the following articles for the most optimal results. Using the right controls will reduce the incidence of errors and help you generate higher quality results. Listed below are some tips for optimizing experiments using the C9 marker:

Benefits

Although the Wu case has demonstrated the potential benefits of CA 19-9 in predicting pancreatic cancer, it should not be considered the sole diagnostic indicator for the disease. Currently, pancreatic cancer is one of the leading causes of cancer-related death and has a five-year survival rate of just four to six percent. Poor prognosis is attributed to late stage presentation, lack of effective treatments and early recurrence, and the lack of clinically useful biomarkers. More studies are needed to maximize the potential of this marker and determine its clinical value in early detection and treatment.